The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Real-world outcomes of frailty subgroups treated with teclistamab: an IMF study database analysis
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the findings of an International Myeloma Foundation (IMF) study database analysis, which assessed the real-world outcomes of frail patients with multiple myeloma (MM) treated with teclistamab. Dr Lin highlights that frail patients showed a trend toward increased severity of cytokine release syndrome (CRS) and hospital stays; however, these effects were not statistically significant, and the clinical response to treatment was comparable to that of non-frail patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
At the ASH 2024 this year, the IMF immunotherapy data registry will also be sharing results across a number of centers in the US and Canada where we looked specifically at patients who meet criteria for frailty and see how their outcome was when they received BCMA-targeting bispecific teclistamab, as standard of care. What we saw was that while there was a trend towards some increased severity of cytokine release syndrome and maybe hospital stays, these were not statistically significant...
At the ASH 2024 this year, the IMF immunotherapy data registry will also be sharing results across a number of centers in the US and Canada where we looked specifically at patients who meet criteria for frailty and see how their outcome was when they received BCMA-targeting bispecific teclistamab, as standard of care. What we saw was that while there was a trend towards some increased severity of cytokine release syndrome and maybe hospital stays, these were not statistically significant. And in particular, the clinical response of these patients was not different from those patients who are not frail. And this does speak to the fact that this is a therapy that while it needs to be given right now in a continuous fashion, if you will, rather than a one-time dose treatment, but it is something that can be adjusted in terms of the frequency and so on based on tolerability while still obtaining response for patients. So this is a very useful tool to have at our disposal to help manage patients with multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
